Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02044757
Other study ID # 12-08545
Secondary ID 6030sc
Status Completed
Phase N/A
First received January 22, 2014
Last updated December 8, 2014
Start date June 2013
Est. completion date August 2014

Study information

Verified date December 2014
Source University of California, Berkeley
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study to investigate the addictive properties of soda and other sugar sweetened beverages (SBBs) in teenagers aged 13-18 years. It is hypothesized that participants who were regularly consuming sweetened and caffeinated beverages will experience symptoms typical of caffeine withdrawal, such as headache and fatigue, during the SSB withdrawal period.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 13 Years to 18 Years
Eligibility Inclusion Criteria:

- Drinks more than 36 ounces of sugar-sweetened beverages per day

- Speaks fluent English

- Parent speaks English or Spanish

- Lives in San Francisco Bay Area

Exclusion Criteria:

- Pregnant or nursing

- Taking medication to address mental health issues

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
SSB withdrawal
During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).

Locations

Country Name City State
United States Children's Hospital and Reasearch Center Oakland Oakland California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Berkeley University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Compliance with intervention to only drink water and unflavored milk during the SSB withdrawal phase Using measure of salivary caffeine, beverage recalls, and 24-hour dietary recalls, we will assess compliance. Days 6-8 No
Primary Symptoms of withdrawal Symptoms of withdrawal during the SSB withdrawal period (days 6-8) will be compared to symptoms of withdrawal during usual consumption period (days 1-3). Three measures are used to assess withdrawal symptoms: Griffiths' withdrawal scale, the relative reinforcing value of soda, and daily check in questions on well-being. Days 1-3 and days 6-8 No
Secondary Change in diet Changes in diet will be assessed by 24-hour dietary recalls and beverage recalls Days 1-2, 6-8 No
Secondary Change in impulsivity Impulsivity will be assessed via the delayed discounting task Days 1 and 8 No
Secondary Change in stress Stress will be assessed via salivary cortisol samples Days 1 and 8 No
Secondary Change in preference for soda Preference for soda will be measured through the Labeled Affective Magnitude Scale (LAMS) and daily check-in questions Days 1-3, 6-8 No
See also
  Status Clinical Trial Phase
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Completed NCT03557294 - Varenicline OTC Trial on Efficacy and Safety Phase 4
Recruiting NCT04850664 - Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder Phase 2
Completed NCT02391571 - A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects Phase 3
Recruiting NCT05834478 - Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 Phase 3
Recruiting NCT05485519 - Prospective, Randomized, Open Label Controlled Trial To Evaluate The Safety And Efficacy Of Dexmedetomidine Use Beyond 24 Hours Compared With Midazolam In Children Admitted To Pediatric Intensive Care Unit at King Abdullah Specialist Children Hospital- Ministry of National Guard Health Affairs. Phase 3